MedTrace Logo

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

NCT05532696 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2024-06-24

No results posted yet for this study

Summary

A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)

Conditions

  • Advanced Solid Tumor
  • Non Small Cell Lung Cancer
  • HER2 Mutations

Interventions

DRUG

ABT-101

Patients will receive ABT-101 by oral administration on a 28-day cycle

Sponsors & Collaborators

  • Anbogen Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-27
Primary Completion
2026-11-30
Completion
2027-05-31
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05532696 on ClinicalTrials.gov